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INFUSIONS ofhaemopoietic cells have now been widely used in the treatment of
various forms of marrow failure. These cells have generally been obtained from
an adult living donor (Mathe et al., 1959), or from the patient before either
chemotherapy (Westbury et al., 1959) or radiotherapy (Newtoii et al., 1959) for
reinfusion after these procedures.
Kay and Constandoulakis (1959) have described a technique whereby the
haemopoietic cells contained in the human foetal liver may be harvested, prepared,
and stored in a form suitable for intravenous infusion. This communication
describes the results obtained in treating fifteen patients suffering from marrow
failure with this material.
MATERIALS AND METHODS
The foetal liver suspensions were kindly supplied to us by Dr. H. E. M. Kay of
The Royal Marsden Hospital, London. They were transported in sealed 5 ml.
ampoules, stored in thermos flasks in a mixture of solid carbon dioxide and
methylated spirits at -79° C. Immediately before use the ampoule was quickly
thawed and the material administered at a rate of 1 ml. per minute into an
intravenous transfusion of blood, not more than 5 ml. amounts being given in any
onie hour. Each patient received between 18 and 25 ml. of this material except
one who was given a total of 35 ml. in two divided doses with a 4-day interval.
Foetal liver infusions have been given in all to fifteen patients with severe
marrow failure. The infusion of this material was possibly associated with ain
untoward reaction in only one patient suffering from toxic marrow failure. Six
hours after the conmpletion ofthe infusion she developed a severe pyrexial reactioni
accompanied by a rigor and circulatory collapse: the temperature rose from
99G' F. to 105-6° F. and her blood pressure, previously 150/90 mm. Hg, fell to
80/40 mm. Hg. She was given 100 mg. hydrocortisone acetate by intravenous
injection and within 8 hours the blood pressure and temperature readings had
returned to their previous levels. There was no subsequent evidence of excess
red cell breakdown to suggest that haemolysis of the transfused red blood cells
had been the main cause of this reaction.
The patients receiving foetal liver suspension can be divided into two distinct
groups. The first of ten patients developed marrow failure following exposure to
cytotoxic drugs, and a second group of five patients in whom there was no known
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Group 1. Patients with toxic marrowfailure
These ten patients all had some form of neoplastic disease. Eight had
disseminated carcinomatosis, five of mammary and three of bronchial origin;
one had Hodgkin's disease; and one had lymphoid reticulosis. The three
patients with bronchial carcinoma had been treated with T.E.M. (tri-ethylene
melamine), while all the remaining patients had had intensive therapy with
Thiotepa (tri-ethylene thiophoramide). Severe leuco- and thrombocytopenia
(white cell count under 200 and/or platelet count below 40,000 per cubic mm.)
was present in all these patients after completion of chemotherapy and persisted
for at least 9 and usually 15-17 days preceding the foetal liver infusion. During
the period of marrow aplasia neither steroid therapy nor transfusions with fresh
blood produced any improvement.
In only three patients of this group of ten did the pancytopenia eventually
resolve and the level of circulating cells reach pre-treatment levels. In the
remaining seven cases there was no improvement in thepancytopenia before death
3-10 days following the foetal liver infusion. In each patient where genotype
differences existed between the donor and the recipient's blood group differential
agglutination studies were carried out using the modification of the Ashby
technique described by Constandoulakis and Kay (1959). There was no firm
evidence from these tests that red blood cells other than ofrecipient genotype were
present in the peripheral blood of these patients. Post mortem examination was
carried out in four of these patients and careful macroscopic and microscopic
examination failed to show any evidence of pulmonary embolism. In each case
there was extensive active malignant disease and the sequelae of marrow failure,
including extensive petechial haemorrhages.
Of the three patients in whom the level of circulating cells reached pre-
treatment levels, in no case was there any evidence that the infused cells survived
permanently. In two patients there was no evidence of any clinical, or of direct
haematological, benefit from the infused cells, but in the remaining patient there
was evidence that the infused cells survived, matured and circulated for a short
period. In this patient with mammary carcinoma the improvement in the clinical
and haematological findings was immediate and striking following the foetal liver
infusion, and normal levels of circulating cells were attained within 30 days.
Examination of the patient's red and white cells in the post-infusion period
suggested their origin in part from the infused cells and the detailed evidence for
this conclusion has been published elsewhere (Bridges et al., 1960). The white
cell and platelet counts remained within normal limits for 24 months during
which the carcinoma was quiescent and the secondary lesions improved and
healed. The patient then relapsed and died 3 months later from generalised
mammary carcinomatosis uncontrolled by a second course of Thiotepa.
In the other two patients with toxic marrow failure which resolved, no rise
in the white cell or platelet counts occurred until 5 days following the infusion.
There is no firm evidence that the infused foetal cells survived or contributed
to the eventual marrow recovery. In these two patients both donor and host
were of blood group 0. In each transfer there were minor differences in geno-
type but blood transfusions given at the same time as the foetal liver made
subsequent genotype analysis of red blood cells inconclusive.
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Group 2. Patients with no known exposure to any toxic agent
This group of five patients all had severe peripheral leuco- and thrombocy-
topenia at the time of foetal liver infusion. Two patients were in the terminal
stages ofFanconi's familialaplastic anaemia; one had idiopathic aplastic anaemia;
one was in the aplastic preleukaemic phase of monocytic leukaemia; and one a
terminal case of paroxysmal nocturnal haemoglobulinuria in the aplastic phase.
None of these patients showed any untoward reaction to the foetal cell infusion.
In no case was there any improvement in the clinical condition, or in the level of
circulating blood cells, while differential agglutinationl studies showed no evidence
of survival of infused cells of foetal origin.
In this group, four patients died within 7 days of the liver infusion. It was
considered that the foetal liver suspensions did not contribute to these deaths as
no evidence of pulmonary embolism was found at autopsy. The remaininig
patient survived for 3 months before death from acute monocytic leukaemia.
DISCUSSION
The prognosis for patients with severe marroMr failure is uncertain but, in
general, if the marrow failure follows exposure to a toxic agent, then the outlook
is somewhat better thani ifthe marrow failure develops spontaneouslv. Therefore,
in attempting to assess the value of infusions of foetal liver cells in our patients,
we feel the two groups should be considered separately.
Of the group of ten patients with severe toxic marrow failure, three eventually
recovered normal marrow function but in no case was there any evidence that the
inifused foetal cells survived permanently. In one patient there was evidence that
the infused cells survived and matured, and that cells of foetal origin circulated in
the patient's peripheral blood for a short period, and may have sustained her until
normal marrow function was resumed. In the other two patients the possibilitv
that some hormonal or nutritional factor was conveyed in the foetal infusions to
these patients remains a possibility, without present proof of validity.
The outlook for patients with toxic marrow failure must depend not only on
the degree of marrow failure but also on their general condition and presence of
aniy other disease. In this regard it is important to note that our three patients
who recovered marrow activity were the only ones whose malignant process had
been favourably influenced by the chemotherapy given. In the other seven
patients, whilst the immediate cause of death was haemorrhage or infectioni
consequent on thrombocytopenia or leucopenia, the malignant process was
disseminated and active and must have contributed substantially as a cause of
death.
In none of our five patients with non-toxic marrow failure was the administra-
tion of foetal liver suspension of any value either clinically or haematologicallv.
However, four of these patients were in the terminal stages of their illness at the
time of infusion and the other died three months later following the developmenit
of frank monocytic blastic leukaemia.
Scott et al. (1961) have reported the results of giving foetal liver suspensioni to
fourteen patients with idiopathic marrow failure and found it to be of temporary
benefit in only two cases. These authors reported Ino untoward reactioii in aniy
of the patients. In the present series in only one instaiice was the administratioii
of foetal liver suspension possibly associated with an adverse reaction. It may beFOETAL LIVER SUSPENSIONS IN MARROW APLASIA 125
this episode of collapse and hyperexia, 6 hours after the foetal liver infusion, was
due to the onset of septicaemia. The patient died some days later and at autopsy
no emboli in the lungs were discovered, nor indeed were pulmonary emboli found
in any other patients autopsied.
Our experience and that of Scott et al. (1961) has proved disappointing and it
must therefore be concluded that at present foetal liver suspensions are of little
therapeutic value in the treatment ofmarrow failure. This finding is in agreement
with the generally disappointing reports ofthe use of suspensions of adult marrow
cells in similar cases. Occasionally, however, startling results are claimed ; the
most striking perhaps being that ofBeilby et al. (1960), who obtained a " take " of
14 months where adult sibling marrow was given following radiotherapy and
chemotherapy for Hodgkin's disease.
It would seem that the early hopes of successful allogenic grafts of haemo-
poietic cells of adult or foetal origin have not been sustained in practice. The
theoretical advantages of foetal cells both in their capacity to provoke a less
severe immunological rejection by the host (Kay and Constandoulakis, 1959) and
their decreased competence to react against host tissues (Barnes, Ilbery and
Loutit, 1958) have not been borne out in clinical use.
SUMMARY
Foetal liver suspenisions have been used to treat fifteen patients with severe
marrow failure.
In a group of ten patients with severe toxic marrow failure, three eventually
recovered normal marrow function, and in only one of these three was there
evidenice that the foetal cells survived for a short period.
In none of the five patients with non-toxic marrow failure was there evidence
that the infused foetal cells were of any haematological or clinical benefit.
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